Clinical Research Directory

Inclusion Criteria: * Subjects with COPD, 40 - 80 yrs of age * Post-bronchodilator forced expiratory volume (FEV)1/forced vital capacity (FVC) ratio 0.7, FEV1% predicted between 40 to 70 * Both active and ex-smokers with at least 10 pack-years history of smoking * COPD patients taking H2 antagonists, loperamide or loratadine and willing to stop during the study period Exclusion Criteria: * Known allergy/sensitivity to quercetin * Subjects with primary current diagnosis of asthma * Upper respiratory tract infection within two weeks of the screening visit * Acute bacterial infection requiring antibiotics within two weeks of screening * Emergency treatment or hospitalization within one month of screening for any reasons * Unwillingness to stop flavonoid supplementation * Dietary intake exceeding or averaging 150 mg quercetin daily as assessed by Bioflavonoid Food and Supplement Screener * Daily warfarin or cyclosporine (Neoral, Sandimmune) * Subjects taking H2 antagonists (cimetidine, ranitidine), loperamide (Imodium) or loratadine and not willing to stop during study period * Lung cancer history or undergoing chemo- or radiation therapy * Inflammatory bowel disease * Women of child-bearing age and unwilling to take pregnancy test * Child-bearing age, who are unwilling to use adequate contraception or abstain during the course of the study. * Pregnant or lactating mothers